Lowering the Cost-of-Goods for making mRNA-based vaccines utilizing continuous mRNA manufacturing

This project advances CAMERNA, a continuous mRNA manufacturing system that reduces cost-of-goods by minimizing reagent use, automating production, and enabling scalable, low-cost vaccine manufacturing for global health access.
Categories
Drug product

Industry Need

There is no currently available Continuous process for end-to-end mRNA synthesis for vaccines.

Solution

The proposed solution leverages CAMERNA, a novel continuous automated manufacturing system, to enable end-to-end production of mRNA drug substance. This continuous, modular approach eliminates the need for DNase, reduces reagent usage, and supports scalable, low-cost, on-demand mRNA vaccine manufacturing.

Impacts

Accelerated mRNA Vaccine Development

Reduction in Cost-of-Goods

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access more, including: 

  • Updates
  • Value Proposition
  • Related Publications
  • Deliverables

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Sepragen Corporation

Sepragen Corporation

Participating Organizations

University of Massachusetts Lowell

University of Massachusetts Lowell